Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model

Vaccine

Volumn 28, Issue 49, 2010, Pages 7787-7796

  Kim, Hye Sung ^a   Park, Hye Mi ^a   Park, Jung Sun ^a   Sohn, Hyun Jung ^a   Kim, Sung Guh ^b   Kim, Hyung Jin ^a   Oh, Seong Taek ^a   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b Boryung Pharm Co Ltd   (South Korea)

Author keywords

Carcinoembryonic antigen; DC vaccine; FOLFIRI; Myeloid derived suppressor cells; Regulatory T cells

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL SPECIFICITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TH1 CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; FLUOROURACIL; LEUCOVORIN; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 78349313304     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.046     Document Type: Article

References (37)

1. Weitz J., Koch M., Debus J., Höhler T., Galle P.R., Büchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
2. Midgley R.S., Kerr D.J. Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther 2003, 3:63-78.
3. Arbuck S.G. Overview: clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989, 63:1036-1044.
4. Saltz L.B., Kanowitz J., Kemeny N.E., Schaaf L., Spriggs D., Staton B.A., et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996, 14:2959-2967.
5. Guichard S., Cussac D., Hennebelle I., Bugat R., Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997, 73:729-734.
6. Rougier P., Bugat R. CTP-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin oncol 1996, 23:34-41.
7. Teufel A., Steinmann S., Siebler J., Zanke C., Hohl H., Adami B., et al. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 2004, 4:38.
8. Blattman J.N., Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 2004, 305:200-205.
9. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
10. Thompson J.A., Grunert F., Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991, 5:344-366.
11. Morse M.A., Clay T.M., Hobeika A.C., Osada T., Khan S., Chui S., et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005, 11:3017-3024.
12. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23:720-731.
13. Matsuda K., Tsunoda T., Tanaka H., Umano Y., Tanimura H., Nukaya I., et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004, 53:609-616.
14. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
15. Cho H.I., Kim H.J., Oh S.T., Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003, 22:224-236.
16. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006, 24:2860-2868.
17. Ojima T., Iwahashi M., Nakamura M., Matsuda K., Nakamori M., Ueda K., et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 2007, 120:585-593.
18. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
19. Muller A.J., Scherle P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006, 6:613-625.
20. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
21. Ko H.J., Kim Y.J., Kim Y.S., Chang W.S., Ko S.Y., Chang S.Y., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007, 67:7477-7486.
22. Liu J.Y., Wu Y., Zhang X.S., Yang J.L., Li H.L., Mao Y.Q., et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007, 56:1597-1604.
23. Eloit M., Gilardi-Hebenstreit P., Toma B., Perricaudet M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J Gen Virol 1990, 71:2425-2431.
24. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176:1693-1702.
25. Heiser A., Dahm P., Yancey D.R., Maurice M.A., Boczkowski D., Nair S.K., et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164:5508-5514.
26. Park M.Y., Kim H.S., Woo S.J., Kim C.H., Park J.S., Sohn H.J., et al. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells. Eur J Immunol 2008, 38:2106-2117.
27. Kim Y.H., Choi B.K., Kim K.H., Kang S.W., Kwon B.S. Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res 2008, 68:7264-7269.
28. Pernis A., Gupta S., Gollob K.J., Garfein E., Coffman R.L., Schindler C., et al. Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells. Science 1995, 269:245-247.
29. Giermasz A.S., Urban J.A., Nakamura Y., Watchmaker P., Cumberland R.L., Gooding W., et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 2009, 58:1329-1336.
30. Park S.D., Kim C.H., Kim C.K., Park J.A., Sohn H.J., Hong Y.K., et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007, 25:3485-3491.
31. Tanaka F., Yamaguchi H., Ohta M., Mashino K., Sonoda H., Sadanaga N., et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer 2002, 101:265-269.
32. Weihrauch M.R., Ansén S., Jurkiewicz E., Geisen C., Xia Z., Anderson K.S., et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005, 11:5993-6001.
33. Yu P., Rowley D.A., Fu Y.X., Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006, 18:226-231.
34. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
35. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-{beta}-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
36. Bourquin C., Schreiber S., Beck S., Hartmann G., Endres S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 2006, 118:2790-2795.
37. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.